


4-phenylmethanamine-6-chloro-2-(1-imidazolyl)-quinazoline

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 157863-27-9 REGISTRY
ED Entered STN: 23 Sep 1994
CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C18 H14 Cl N5
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



↑
CA Registry
name for
the same
compound

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

→ (attached)
fig.

=> file reg
FILE 'REGISTRY' ENTERED AT 17:36:09 ON 11 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUL 2005 HIGHEST RN 854370-36-8
DICTIONARY FILE UPDATES: 10 JUL 2005 HIGHEST RN 854370-36-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> file caplus
FILE 'CAPLUS' ENTERED AT 17:36:12 ON 11 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 11 Jul 2005 VOL 143 ISS 3
FILE LAST UPDATED: 10 Jul 2005 (20050710/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d que L9

L4 38 SEA FILE=REGISTRY ABB=ON PLU=ON (118-92-3/BI OR 120-73-0/BI OR 127488-00-0/BI OR 12766-00-6/BI OR 127957-37-3/BI OR 128173-55-7/BI OR 132737-08-7/BI OR 134485-90-8/BI OR 15018-66-3/BI OR 150452-18-9/BI OR 152712-47-5/BI OR 153447-99-5/BI OR 157863-27-9/BI OR 158001-76-4/BI OR 158001-83-3/BI OR 159687-16-8/BI OR 179042-24-1/BI OR 179042-25-2/BI OR 179042-26-3/BI OR 179042-27-4/BI OR 179042-28-5/BI OR 179042-29-6/BI OR 179042-30-9/BI OR 179042-31-0/BI OR 19006-82-7/BI OR 253-82-7/BI OR 254-61-5/BI OR 275-94-5/BI OR 289-95-2/BI OR 315-30-0/BI OR 33643-94-6/BI OR 37294-42-1/BI OR 51-17-2/BI OR 591-54-8/BI OR 6025-68-9/BI OR 73-40-5/BI OR 79030-08-3/BI OR 9068-52-4/BI)

L5 14 SEA FILE=REGISTRY ABB=ON PLU=ON L4 AND NCNC2/ESS

L6 8 SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND NCNC3/ESS

L7 5 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND C6/ESS

L8 1 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND CL>0

L9 5 SEA FILE=CAPLUS ABB=ON PLU=ON L8

=> d L9 ibib abs hitind hitstr 1-5

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:441612 CAPLUS

DOCUMENT NUMBER: 133:63991

TITLE: cGMP phosphodiesterase 5 inhibitors for inhalation in the treatment of sexual dysfunction

INVENTOR(S): Naef, Reto

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037061	A2	20000629	WO 1999-EP10250	19991221
WO 2000037061	A3	20001026		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2355368	AA	20000629	CA 1999-2355368	19991221
EP 1140044	A2	20011010	EP 1999-964644	19991221
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002532542	T2	20021002	JP 2000-589172	19991221
US 2001055570	A1	20011227	US 2001-883572	20010618
US 2004214831	A1	20041028	US 2004-851603	20040521
PRIORITY APPLN. INFO.:			GB 1998-28340	A 19981222
			WO 1999-EP10250	W 19991221

US 2001-883572 A1 20010618

AB Treatment of sexual dysfunction is carried out by inhalation of a cGMP PDE 5 inhibitor, especially, 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (I), 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)pyrazolo[3,4-d]pyrimidin-4-one. Gelatin capsules suitable for use in a capsule inhaler are prepared, each capsule containing a dry powder consisting of 10 mg I, which had been ground to a mean particle diameter of 1-5 μm , and 10 mg of lactose monohydrate having a particle diameter below 212 μm . These capsules are used in the treatment of erectile dysfunction patients by inserting a capsule into the capsule chamber of an inhaler.

IC ICM A61K031-00


CC 63-6 (Pharmaceuticals)

IT 139755-83-2 157862-73-2 **157863-27-9** 158020-82-7
168464-34-4
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (cGMP phosphodiesterase inhibitors for inhalation in treatment of sexual dysfunction)

IT **157863-27-9**
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (cGMP phosphodiesterase inhibitors for inhalation in treatment of sexual dysfunction)

RN 157863-27-9 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:458023 CAPLUS

DOCUMENT NUMBER: 125:105160

TITLE: Inhibitors of cGMP phosphodiesterase for the treatment of erectile dysfunction and other disorders

INVENTOR(S): Campbell, Simon Fraser; Mackenzie, Alexander Roderick; Wood, Anthony

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Research and Development Company, N.V./s.A.; Pfizer Inc.

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

```

-----
WO 9616644      A1      19960606      WO 1995-EP4066      19951016
  W: CA, FI, JP, MX, US
  RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2203379      AA      19960606      CA 1995-2203379      19951016
EP 793486      A1      19970910      EP 1995-936507      19951016
  R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
JP 09512834      T2      19971222      JP 1995-517126      19951016
JP 2975990      B2      19991110
JP 11343238      A2      19991214      JP 1999-105626      19951016
US 6300335      B1      20011009      US 1997-836670      19970522
FI 9702205      A      19970523      FI 1997-2205      19970523
US 2001044441      A1      20011122      US 2001-880141      20010613
US 6656945      B2      20031202
JP 2004091490      A2      20040325      JP 2003-308939      20030901
US 2004087599      A1      20040506      US 2003-694644      20031027
PRIORITY APPLN. INFO.:
                                GB 1994-23910      A 19941126
                                JP 1996-517126      A3 19951016
                                JP 1999-105626      A3 19951016
                                WO 1995-EP4066      W 19951016
                                US 1997-836670      A3 19970522
                                US 2001-880141      A3 20010613

AB  Compds. which are selective inhibitors of cGMP phosphodiesterase are
    useful in the treatment of erectile dysfunction (impotence) in male
    animals, including man. The cGMP phosphodiesterase inhibitors can also be
    used to treat female sexual dysfunction, premature labor, or dysmenorrhea.
    Specific compds., as well as compds. from other patents, are claimed.

IC  ICM A61K031-00
CC  1-12 (Pharmacology)
IT  51-17-2D, Benzimidazole, derivs. 73-40-5D, Guanine, derivs. 118-92-3D,
    Anthranilic acid, derivs. 120-73-0D, Purine, derivs. 253-82-7D,
    Quinazoline, derivs. 254-61-5D, Pyrido[2,3-d]pyrimidine, derivs.
    275-94-5D, Cycloheptimidazole, derivs. 289-95-2D, Pyrimidine, derivs.
    315-30-0D, derivs. 591-54-8D, 4-Aminopyrimidine, derivs. 6025-68-9D,
    Pyrrolo[1,2-a]quinoxalin-4(5H)-one, derivs. 12766-00-6D, Quinazolinone,
    derivs. 15018-66-3D, 4-Aminoquinazoline, derivs. 19006-82-7D, derivs.
    33643-94-6D, derivs. 37294-42-1D, Imidazoquinazoline, derivs.
    79030-08-3D, Griseolic acid, derivs. 127488-00-0 127957-37-3
    128173-55-7 132737-08-7 134485-90-8 150452-18-9 152712-47-5
    153447-99-5 157863-27-9 158001-76-4 158001-83-3
    159687-16-8 179042-24-1D, derivs. 179042-25-2D, derivs.
    179042-26-3D, Imidazo[1,5-a]quinoxalin-4(5H)-one, derivs. 179042-27-4
    179042-28-5 179042-29-6 179042-30-9 179042-31-0
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (cGMP phosphodiesterase inhibitors for treatment of erectile
        dysfunction and other disorders)

IT  157863-27-9
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (cGMP phosphodiesterase inhibitors for treatment of erectile
        dysfunction and other disorders)

RN  157863-27-9 CAPLUS
CN  4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (9CI)
    (CA INDEX NAME)

```